Holen Sie sich die Stockscreener-App
7.055
6.16%
0.395
Schlusskurs vom Vortag:
$6.66
Offen:
$6.79
24-Stunden-Volumen:
226.29K
Relative Volume:
0.21
Marktkapitalisierung:
$329.49M
Einnahmen:
$20.72M
Nettoeinkommen (Verlust:
$-100.84M
KGV:
-2.6523
EPS:
-2.66
Netto-Cashflow:
$-78.56M
1W Leistung:
+0.00%
1M Leistung:
-2.75%
6M Leistung:
+85.08%
1J Leistung:
-57.97%
1-Tages-Spanne:
$6.7618
$7.13
1-Wochen-Bereich:
$6.60
$7.13
52-Wochen-Spanne:
$2.235
$17.41
4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile
Firmenname
4 D Molecular Therapeutics Inc
Sektor
Branche
Telefon
(510) 505-2680
Adresse
5858 HORTON STREET #455, EMERYVILLE
Vergleichen Sie FDMT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
7.055 | 311.04M | 20.72M | -100.84M | -78.56M | -2.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
386.12 | 99.26B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.61 | 62.06B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
447.34 | 59.21B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
729.89 | 44.94B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
339.31 | 36.57B | 3.81B | -644.79M | -669.77M | -6.24 |
4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-13 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-11-21 | Eingeleitet | Morgan Stanley | Underweight |
| 2024-09-23 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2024-04-15 | Eingeleitet | Barclays | Overweight |
| 2024-02-07 | Fortgesetzt | Goldman | Buy |
| 2023-10-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-18 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2023-01-30 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-11-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-11-15 | Hochstufung | Goldman | Neutral → Buy |
| 2022-08-12 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-06-22 | Eingeleitet | Jefferies | Buy |
| 2022-01-04 | Eingeleitet | SVB Leerink | Outperform |
| 2021-01-05 | Eingeleitet | BofA Securities | Buy |
| 2021-01-05 | Eingeleitet | Evercore ISI | Outperform |
| 2021-01-05 | Eingeleitet | Goldman | Neutral |
Alle ansehen
4 D Molecular Therapeutics Inc Aktie (FDMT) Neueste Nachrichten
4D Molecular Therapeutics, Inc. $FDMT Shares Bought by Acadian Asset Management LLC - Defense World
Will 4D Molecular Therapeutics Inc. continue its uptrendJuly 2025 Market Mood & High Yield Stock Recommendations - newser.com
Rate Hike: What hedge funds are buying 4D Molecular Therapeutics Inc2025 Technical Patterns & Accurate Buy Signal Alerts - خودرو بانک
Pullback Watch: How sensitive is 4D Molecular Therapeutics Inc. to inflation2025 Buyback Activity & Free Real-Time Market Sentiment Alerts - خودرو بانک
4D Molecular Therapeutics (NASDAQ:FDMT) Given "Sell (D-)" Rating at Weiss Ratings - MarketBeat
Trend analysis for 4D Molecular Therapeutics Inc. this weekTrade Ideas & AI Powered Market Entry Ideas - newser.com
New Highs: Will 4D Molecular Therapeutics Inc outperform its industry peersJuly 2025 Price Swings & Fast Momentum Stock Entry Tips - خودرو بانک
4D Molecular Therapeutics (NASDAQ:FDMT) Given “Sell (D-)” Rating at Weiss Ratings - Defense World
Levels Update: What is the Moat Score of 4D Molecular Therapeutics IncQuarterly Trade Report & Free Technical Pattern Based Buy Signals - خودرو بانک
Sentiment Recap: Will 4D Molecular Therapeutics Inc benefit from geopolitical trendsJuly 2025 Pullbacks & Smart Allocation Stock Reports - خودرو بانک
Risk Check: Can 4D Molecular Therapeutics Inc sustain its profitabilityWeekly Investment Recap & Accurate Entry/Exit Alerts - خودرو بانک
Cubist Systematic Strategies LLC Sells 364,659 Shares of 4D Molecular Therapeutics, Inc. $FDMT - MarketBeat
What drives Millicom International Cellular SAs stock priceEarnings Recap Report & Fast Exit and Entry Strategy Plans - خودرو بانک
What MACD and RSI say about 4D Molecular Therapeutics Inc.2025 Historical Comparison & AI Powered Buy and Sell Recommendations - newser.com
Applying Wyckoff theory to 4D Molecular Therapeutics Inc. stock2025 Risk Factors & AI Based Buy and Sell Signals - newser.com
How to forecast 4D Molecular Therapeutics Inc. trends using time seriesShort Setup & Real-Time Volume Triggers - newser.com
4DMT Announces New Employment Inducement Grants - GlobeNewswire
Biotech Leader 4DMT Issues 40,900 Restricted Stock Units to Attract Key Non-Executive Talent - Stock Titan
Building trade automation scripts for 4D Molecular Therapeutics Inc.2025 Risk Factors & AI Powered Market Entry Strategies - Newser
How moving averages guide 4D Molecular Therapeutics Inc. tradingWeekly Trade Recap & Free High Return Stock Watch Alerts - Newser
4D Molecular Therapeutics Inc. stock trendline breakdownQuarterly Earnings Report & Fast Exit/Entry Strategy Plans - Newser
Should you wait for a breakout in 4D Molecular Therapeutics Inc.Market Weekly Review & Safe Capital Growth Tips - Newser
Visual analytics tools that track 4D Molecular Therapeutics Inc. performancePortfolio Value Report & Risk Adjusted Swing Trade Ideas - Newser
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $30.40 Average Target Price from Analysts - MarketBeat
Ranking 4D Molecular Therapeutics Inc. among high performing stocks via toolsJuly 2025 Sector Moves & Stepwise Entry/Exit Trade Alerts - Newser
Chart based exit strategy for 4D Molecular Therapeutics Inc.Weekly Trend Summary & Risk Managed Investment Strategies - Newser
What indicators show strength in 4D Molecular Therapeutics Inc.Global Markets & Risk Controlled Daily Plans - Newser
Volume spikes in 4D Molecular Therapeutics Inc. stock – what they mean2025 Market Trends & Verified Entry Point Signals - Newser
GenVivo Strengthens Oncology Leadership with Appointment of Noriyuki Kasahara, M.D., Ph.D., as Chief Scientific Officer - GlobeNewswire Inc.
Regression analysis insights on 4D Molecular Therapeutics Inc. performanceAnalyst Upgrade & Verified Swing Trading Watchlists - Newser
What candlestick patterns are forming on 4D Molecular Therapeutics Inc.Weekly Profit Report & Growth Focused Entry Reports - Newser
4D Molecular Therapeutics, Inc. $FDMT Shares Bought by Invesco Ltd. - MarketBeat
How to track smart money flows in 4D Molecular Therapeutics Inc.Quarterly Profit Report & Reliable Trade Execution Plans - Newser
Is 4D Molecular Therapeutics Inc. a candidate for recovery playPortfolio Return Report & Step-by-Step Trade Execution Guides - Newser
Is 4D Molecular Therapeutics Inc. meeting your algorithmic filter criteriaJuly 2025 EndofMonth & Reliable Trade Execution Plans - Newser
Can 4D Molecular Therapeutics Inc. hit a new high this monthJuly 2025 Highlights & Free Risk Controlled Daily Trade Plans - Newser
Nuveen LLC Acquires Shares of 150,314 4D Molecular Therapeutics, Inc. $FDMT - MarketBeat
Detecting support and resistance levels for 4D Molecular Therapeutics Inc.Weekly Trend Recap & High Conviction Buy Zone Picks - Newser
How to escape a deep drawdown in 4D Molecular Therapeutics Inc.Weekly Profit Summary & Verified Entry Point Detection - Newser
Pattern recognition hints at 4D Molecular Therapeutics Inc. upsideDollar Strength & High Return Stock Watch Alerts - Newser
Reversal indicators forming on 4D Molecular Therapeutics Inc. stockWeekly Stock Summary & Consistent Profit Trade Alerts - Newser
Transcript : 4D Molecular Therapeutics, Inc. Presents at Morgan Stanley 23rd Annual Global Healthcare Conference, Sep-09-2025 01 - MarketScreener
Real time social sentiment graph for 4D Molecular Therapeutics Inc.2025 Trading Volume Trends & High Accuracy Swing Trade Signals - Newser
Finanzdaten der 4 D Molecular Therapeutics Inc-Aktie (FDMT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.38%
0.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):